Utility of plasma circulating DNA tumor fraction in bone-only metastatic breast cancer: a real-world outcomes study.

ABSTRACT:

Purpose

Bone metastases develop in 50-70% of patients with metastatic breast cancer (MBC), with around one-third having bone as only site of distant disease (bone-only [BO]). Standard imaging is frequently insufficient to track bone metastases. Evidence suggests that circulating tumor DNA (ctDNA) tumor fraction (TF) is prognostic in MBC. We hypothesized that TF would be detectable and prognostic for BO-MBC.

Methods

MBC patients who underwent FoundationOne LiquidCDX comprehensive genomic profiling within 60 days before starting therapy were included. Clinical data was obtained from the nationwide deidentified Flatiron Health/Foundation Medicine Clinico-Genomic Database between 01/2011 and 12/2023.

Results

We identified 778 patients for inclusion: 299 TF < 1% (TF-low),

SUBMITTER: Bader G 

PROVIDER: S-EPMC12209397 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature